Logo for Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Investor Relations Material

Latest events

Logo for Vertex Pharmaceuticals Inc

Q2 2025

Vertex Pharmaceuticals
Logo for Vertex Pharmaceuticals

Q2 2025

4 Aug, 2025
Logo for Vertex Pharmaceuticals

Q1 2025

5 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies

Latest reports from Vertex Pharmaceuticals Inc

Access all reports
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. Its products include KALYDECO (ivacaftor), ORKAMBI (lumacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), VX-445, and VX-659, as well as other product candidates at various stages of research, development, and commercialization. The company has collaboration agreements with CRISPR Therapeutics AG; Moderna, Inc.; CRISPR Therapeutics AG; Editas Medicine, Inc.; Frontline BioVentures; Merck & Co., Inc.; Cystic Fibrosis Foundation Therapeutics, Incorporated; Bristol-Myers Squibb Company; Altimmune, Inc.; and Tesaro, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.